[{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Moves Forward with Clinical Development of Neihulizumab in Steroid-Refractory Acute Graft-Vs-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab in Patients with Steroid-Refractory Acute Graft-versus-Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"AltruBio","sponsor":"AbGenomics B.V","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio\u2019s Neihulizumab Granted Fast Track Designation by the FDA for Steroid Refractory Acute Graft Versus Host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"AltruBio","sponsor":"aMoon","pharmaFlowCategory":"D","amount":"$63.0 million","upfrontCash":"Undisclosed","newsHeadline":"Altrubio Raises $63 Million Series A Round to Continue Its Company Transformation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio to Present Abstract on Checkpoint Regulator Neihulizumab as a Novel Therapy for Immunological Diseases at the B&T Cell-Mediated Autoimmune Disease Drug Development Virtual Summit","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces Completion of Enrollment in Phase 1 Clinical Study of Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio to Present New Phase 1b Data Evaluating Neihulizumab (ALTB-168) in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces FDA Clearance of IND Application for ALTB-268, a Next-Generation Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"IND Enabling"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces Poster Presentation on Immune Checkpoint Enhancer, ALTB-168 at Crohn\u2019s & Colitis Congress 2023","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase II"},{"orgOrder":0,"company":"AltruBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AltruBio Announces First Patient Dosed in Phase 1 Trial of Next-Generation Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by AltruBio
ALTB-268 is a next-generation PSGL-1 antibody agonist that acts as an immune checkpoint enhancer (ICE) that downregulates chronically activated T-cells by inhibiting the T-cell effector function, promoting T-cell exhaustion and apoptosis.
ALTB-168 (neihulizumab) is an immune checkpoint enhancer that regulates T cell homeostasis. This agonist antibody maintains T cell homeostasis by downregulating of activated T cells, potentially sparing resting T cells and early-activated T cells thus controlling inflammation.
The company will share development plans for next generation immune checkpoint enhancer, ALTB-268, bearing the same mechanism of action with increased potency for subcutaneous administration in ulcerative colitis patients.
ALTB-268 is a next-generation PSGL-1 antibody agonist that acts as an immune checkpoint enhancer (ICE) that downregulate chronically activated T-cells by inhibiting the T-cell effector function, promoting T-cell exhaustion and apoptosis.
Neihulizumab (ALTB-168) is an immune checkpoint enhancer that regulates T cell homeostasis, unique mechanism of action of this agonist antibody maintains T cell homeostasis by preferentially inducing downregulation of activated T cells.
ALTB-168 (neihulizumab), is immune checkpoint agonist antibody that regulates T cell homeostasis, unique mechanism of action provides a natural regulation of T cell homeostasis that induces cell death.
Neihulizumab, is a first-generation immune checkpoint regulator targeting PSGL-1 that is capable of selectively depleting chronically activated T cells and achieving natural immune homeostasis against immunological diseases.
AltruBio has implemented a new focus on its novel PSGL-1 program for immunological diseases, and the Company has now secured the funds to continue advancing the program. including Neihulizumab.
Neihulizumab is an immune checkpoint regulator targeting PSGL-1, triggering the depletion of chronically activated T cells. It is currently being studied in a Phase 1b multi-dose trial in SR-aGVHD.
The trial is a multi-dose study of Neihulizumab in SR-aGVHD and follows its successful Phase 1a single-dose study which demonstrated a 77% response rate.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
